Journal of Central Nervous System Disease (Mar 2022)

Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis

  • Michael Auer MD PhD,
  • Harald Hegen MD PhD PD,
  • Anna Hotter MD,
  • Wolfgang Löscher MD MSc,
  • Klaus Berek MD,
  • Anne Zinganell MD,
  • Elena Fava MD,
  • Paul Rhomberg MD,
  • Florian Deisenhammer MD MSc,
  • Franziska Di Pauli MD PhD

DOI
https://doi.org/10.1177/11795735221084837
Journal volume & issue
Vol. 14

Abstract

Read online

The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple sclerosis (MS), whereas there is no evidence for its use in CIDP so far. We present a patient suffering from CIDP and MS, both refractory to standard treatment and both showing marked improvement on ocrelizumab. To the best of our knowledge, this is a unique report of CIDP with an almost full electrophysiological recovery on ocrelizumab which could be considered as a potential treatment option for refractory CIDP.